News and Events
Subscribe to the CDI Press Releases RSS Feed

Press Releases

Subscribe to the CDI Press Releases RSS Feed

In the News

Events

Awards & Accolades

Subscribe to the CDI Press Releases RSS Feed

eNewsletter Archive

Media Library

Subscribe to CDI News Updates

MEDIA CONTACT:
Joleen Rau
Senior Director
Investor Relations & Corporate Communications
Cellular Dynamics International, Inc.
(608) 310-5142
Contact Media Relations

NIH-CRM Awards Cellular Dynamics up to $7 Million to Produce Human Induced Pluripotent Stem Cells and Differentiated Tissue Cells

MADISON, WIS, October 24, 2012—The National Institutes of Health Center for Regenerative Medicine (NIH-CRM) has awarded Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, a contract to provide human iPS cell lines and terminally differentiated tissue cells from normal or specified patient populations. The contract is worth up to $7.0 million for the three year life of the agreement. This contract follows on two NIH-CRM contracts awarded in September 2011, whereby CDI will generate and genetically engineer iPS cell lines; the company has delivered on several of these cell lines already.

This contract meets a primary goal of the NIH-CRM: to provide researchers with the support needed to move stem cell technology forward. It is expected that these cells will be utilized for preclinical research, including screening compound libraries. As one of the only companies in the world capable of providing iPSC-derived tissue cells in the quality, quantity, and purity required for preclinical research, CDI currently manufactures iCell® Cardiomyocytes, iCell Neurons, iCell Endothelial Cells, and iCell Hepatocytes. In addition, the company launched its MyCell Products in June this year, whereby researchers can contract CDI to manufacture iPS cells and tissue cells, as well as do genetic engineering, for patient samples they supply.

"This contract enables NIH researchers to easily access our human iPS cell-derived cells and accelerate the pace of their research," said Chris Parker, Chief Commercial Officer of CDI. "Scientists can now concentrate on their experiments and the data they generate instead of trying to manufacture a consistent and pure supply of human cells. Our expertise is providing the necessary tools—human cells—so that researchers can focus on discoveries."

Robert Palay, Chief Executive Officer of CDI, continued, "CDI was founded on Dr. James Thomson's vision that the industrial manufacture of human iPS cells and the somatic cells derived from them is critical for discoveries and benefits to human health to be realized. This NIH contract award recognizes CDI's leadership in developing iPSC technology and providing high quality cellular tools to the biological research community in their drive toward improving human health."

About Cellular Dynamics International, Inc.

Cellular Dynamics International (CDI), a FUJIFILM company, is a leading developer and manufacturer of human cells used in drug discovery, toxicity testing, stem cell banking, and cell therapy development. The Company partners with innovators from around the world to combine biologically relevant human cells with the newest technologies to drive advancements in medicine and healthier living. CDI’s technology offers the potential to create induced pluripotent stem cells (iPSCs) from anyone, starting with a standard blood draw, and followed by the powerful capability to develop into virtually any cell type in the human body. Our proprietary manufacturing system produces billions of cells daily, resulting in inventoried iCell® products and donor-specific MyCell® Products in the quantity, quality, purity, and reproducibility required for drug and cell therapy development. Founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research, Cellular Dynamics is based in Madison, Wisconsin, with a second facility in Novato, California. For more information, please visit www.cellulardynamics.com, and follow us on Twitter @CellDynamics

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2015, the company had global revenues of $20.8 billion, at an exchange rate of 120 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.